Lilly's weight-loss pill wins US approval

By Leah Douglas and Christy Santhosh

April 1 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's LLY.N weight-loss pill, making it the second to market after Novo Nordisk's NOVOb.CO oral Wegovy, as the companies fight to capture more customers with the convenience of pills over injectables.

The Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral medication designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss.